In addition to this lack of efficacy, long term trials with Bevacizumab concluded that excessive neutralization of VEGF with high doses or prolonged exposure caused vascular regression and promoted hypoxia (84, 85), driving the selection of more invasive cancer cells that can contribute to tumor resistance and increased metastatic potential (84). The gene discussed is VEGFA; the disease is neoplasm.